PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

This is a randomized trial evaluating the results of using of PARP inhibitor combined with angiogenesis inhibitor. in patients with homologous recombination deficient primary ovarian cancer, fallopian-tube cancer, or primary peritoneal cancer of the III-IV stages.

Trial Details

NCT ID
NCT07472140
Phase
PHASE2 / PHASE3
Sponsor
N.N. Alexandrov National Cancer Centre
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • PARP inhibitor + Bevacizumab
  • PARP inhibitor
Locations (sample)
  • Minsk, Lesnoy, Belarus|53.90019,27.56653

Key Eligibility Criteria

  • Age ≥18-≤75 years.
  • Histologically confirmed diagnosis of serous or endometrioid high-grade ovarian cancer, fallopian-tube cancer or primary peritoneal cancer.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Possibility of performing diagnostic laparoscopy or cytoreductive surgery.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →